GIP
KRYS icon

Granite Investment Partners’s Krystal Biotech KRYS Stock Holding History

Granite Investment Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2M Buy
32,837
+8,553
+35% +$2.56M 0.63% 57
2026
Q1 		$6.27M Sell
24,284
-1,476
-6% -$393K 0.39% 93
2025
Q4 		$6.35M Buy
+25,760
New +$5.42M 0.38% 90

Other funds holding KRYS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Granite Investment Partners's KRYS Position: Q2 2026 in Review

Granite Investment Partners increased its Krystal Biotech (KRYS) stake by 35% in Q2 2026, buying an estimated $2.56M and bringing the position to 32,837 shares worth $12.2M. The position accounts for 0.63% of the portfolio, ranked #57.

Granite Investment Partners first reported a position in KRYS in Q4 2025 and has held it in 3 quarters since. 191 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Granite Investment Partners held 32,837 shares of Krystal Biotech worth $12.2M as of Q2 2026.
  • Granite Investment Partners bought 8,553 Krystal Biotech shares in Q2 2026, an estimated $2.56M.
  • Krystal Biotech made up 0.63% of Granite Investment Partners's portfolio in Q2 2026, its #57 holding.
  • Granite Investment Partners first reported a position in Krystal Biotech in Q4 2025 and has held it in 3 quarters since.
  • 191 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Granite Investment Partners's 13F filing for Q2 2026, filed 7 Aug 2026.